SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 190 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $330,000 | -38.0% | 44,000 | -25.4% | 0.14% | -44.6% |
Q3 2021 | $532,000 | -33.7% | 59,000 | -11.9% | 0.25% | -31.0% |
Q2 2021 | $802,000 | -13.5% | 67,000 | -9.5% | 0.36% | -20.3% |
Q1 2021 | $927,000 | -25.7% | 74,000 | -7.5% | 0.45% | -28.1% |
Q4 2020 | $1,248,000 | +58.2% | 80,000 | -4.2% | 0.63% | +42.9% |
Q3 2020 | $789,000 | +5.5% | 83,500 | 0.0% | 0.44% | -9.1% |
Q2 2020 | $748,000 | +134.5% | 83,500 | +67.0% | 0.48% | +89.5% |
Q1 2020 | $319,000 | +0.3% | 50,000 | +31.6% | 0.26% | +23.1% |
Q4 2019 | $318,000 | -7.6% | 38,000 | 0.0% | 0.21% | -16.5% |
Q3 2019 | $344,000 | -15.9% | 38,000 | 0.0% | 0.25% | -17.3% |
Q2 2019 | $409,000 | +4.6% | 38,000 | -7.3% | 0.30% | +4.9% |
Q1 2019 | $391,000 | -35.7% | 41,000 | -22.6% | 0.29% | -42.8% |
Q4 2018 | $608,000 | -32.3% | 53,000 | 0.0% | 0.50% | -18.5% |
Q3 2018 | $898,000 | +21.7% | 53,000 | +1.9% | 0.62% | +11.4% |
Q2 2018 | $738,000 | -99.9% | 52,000 | +13.0% | 0.55% | -16.6% |
Q1 2018 | $874,000,000 | – | 46,000 | – | 0.66% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |